Evidence map›Paper›PMID 35820778›Full record

Trial reportSexually transmitted infections2023

Spontaneous clearance of asymptomatic anogenital and pharyngeal

Buhari Teker, Henry de Vries, Titia Heijman, Alje van Dam, Maarten Schim van der Loeff, Vita Willemijn Jongen

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled TrialEquivalence Trial
In one paragraph

Trial report in Sexually transmitted infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03294395 (New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03294395 phase3completednot on this map

New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial

TypeinterventionalSponsorPublic Health Service of AmsterdamRan2017 to 2020Enrolled346ConditionsGonorrheaArmsErtapenem 1000 MG, Fosfomycin Oral Suspension, Gentamicin Sulfate, Injectable, Ceftriaxone
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Evaluating a new partner management strategy for bacterial sexually transmitted infections after a change in 2020 in Amsterdam, the Netherlands, 2017 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
  3. Article
  4. To culture or not to culture: correlatingSexually transmitted infections · 2026
    Article
  5. Article
  6. Article
  7. Increase inSexually transmitted infections · 2025
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Buhari TekerDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-1526-7977
Henry de VriesDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
Titia HeijmanDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
Alje van DamDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
Maarten Schim van der LoeffDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-4903-7002
Vita Willemijn JongenDepartment of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands vjongen@ggd.amsterdam.nl.ORCID 0000-0001-9538-1501
GGD Amsterdam · NLAmsterdam UMC Location University of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSpontaneous clearance of asymptomatic

methodsThe NABOGO trial (Trial registration number: NCT03294395) was a randomised controlled, double-blind, single-centre trial assessing non-inferiority of ertapenem, gentamicin and fosfomycin to ceftriaxone for treatment of uncomplicated gonorrhoea. For asymptomatic NABOGO participants, we collected pre-enrolment and enrolment visit samples before trial medication was given. Spontaneous clearance was defined as a positive pre-enrolment nucleic acid amplification test (NAAT) result, followed by a negative NAAT at enrolment. We compared the median time between pre-enrolment and enrolment visits for patients who cleared spontaneously and for those who did not. Determinants of spontaneous clearance were assessed using logistic regression.

resultsThirty-two of 221 (14.5%) anal NG infections cleared spontaneously, 17 of 91 (18.7%) pharyngeal, 3 of 13 (23.1%) vaginal and 9 of 28 (32.1%) urethral NG infections. The median time between the pre-enrolment and enrolment visit was longer for patients who cleared their pharyngeal infection spontaneously compared with those who did not (median 8 days (IQR=7-11) vs 6 days (IQR=4-8), p=0.012); no determinants of clearance at other sites were identified. Overall, patients with more days between the pre-enrolment and enrolment visit were more likely to clear spontaneously (adjusted OR=1.06 per additional day, 95% CI 1.01 to 1.12). No association between location of NG infection and spontaneous clearance was found.

conclusionsA significant proportion of asymptomatic patients cleared their NG infections spontaneously. Given these results, treatment of all NG infections after a one-time NAAT may be excessive, and more research on the natural history of NG is needed to improve antibiotic stewardship.

Indexed as

Chlamydia InfectionsGonorrheaAnti-Bacterial AgentsCeftriaxoneFemaleHumansNeisseria gonorrhoeaeNucleic Acid Amplification TechniquesPharynxAnti-Bacterial AgentsCeftriaxoneGonorrheaNEISSERIA GONORRHOEAESEXUAL HEALTH

Identifiers

PMID35820778
PMCPMC10314023
OpenAlexW4285090640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.